Lupin signs an agreement with National Chemical Laboratory & DST

dc.date.accessioned	2018-06-06T09:22:43Z
dc.date.available	2018-06-06T09:22:43Z
dc.date.issued	2018-03-08
dc.identifier.uri	http://hdl.handle.net/20.500.12252/3941
dc.description	Pharma major Lupin has signed an agreement with CSIR-National Chemical Laboratory (CSIR-NCL, Pune) and Department of Science and Technology, (DST, Delhi) for conducting research on a continuous purification process development of a biosimilar monoclonal antibody therapeutic (mAb). Through this research collaboration, CSIR-NCL and Lupin would together work towards the development of a novel continuous purification process for manufacturing mAb therapeutics.	en_US
dc.language.iso	en	en_US
dc.publisher	Times of India	en_US
dc.subject	Continuous Purification Process Development	en_US
dc.subject	Biosimilar Monoclonal Antibody Therapeutic	en_US
dc.subject	Controlled Chromatography Processes	en_US
dc.subject	Biopharmaceuticals	en_US
dc.subject	Biologics	en_US
dc.subject	Monoclonal Antibodies	en_US
dc.title	Lupin signs an agreement with National Chemical Laboratory & DST	en_US
dc.type	Newspaper Article	en_US
local.division.division	Chemical Engineering and Process Development Division